Xenon Pharmaceuticals (XENE) Projected to Post Quarterly Earnings on Monday

Key Points

• Xenon Pharmaceuticals is set to report Q1 2026 results after the close on Monday, May 11, with analysts forecasting EPS of ($1.17) and revenue of about $1.36 million, following a prior-quarter EPS miss and consensus expectations of roughly -$5 EPS for the current and next fiscal years.
• Shares traded at $57.33 (up ~2.1%) with a market cap of $5.54 billion, and Wall Street has a consensus Buy rating and a mean price target of $73.13, with several firms issuing targets up to $97.
• Insiders sold roughly 296,707 shares (~$17.8M) in the past 90 days (insider ownership 4.07%), while institutional investors own about 95.45% of the stock.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) is expected to be issuing its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect the company to announce earnings of ($1.17) per share and revenue of $1.3640 million for the quarter. Investors may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same quarter in the prior year, the firm earned ($0.84) earnings per share. On average, analysts expect Xenon Pharmaceuticals to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Xenon Pharmaceuticals Trading Up 2.1%

NASDAQ:XENE traded up $1.20 on Monday, hitting $57.33. 292,834 shares of the company's stock traded hands, compared to its average volume of 1,286,312. Xenon Pharmaceuticals has a 1 year low of $28.19 and a 1 year high of $63.95. The firm has a 50-day moving average price of $53.79 and a 200-day moving average price of $46.29. The company has a market cap of $5.54 billion, a PE ratio of -13.17 and a beta of 0.65.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on XENE shares. Guggenheim reaffirmed a "buy" rating and set a $90.00 target price on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Robert W. Baird lifted their price target on Xenon Pharmaceuticals from $63.00 to $97.00 and gave the company an "outperform" rating in a report on Monday, March 9th. Morgan Stanley set a $97.00 price target on Xenon Pharmaceuticals in a report on Monday, March 9th. Stifel Nicolaus set a $66.00 price target on Xenon Pharmaceuticals in a report on Tuesday, February 10th. Finally, Wells Fargo & Company lifted their price target on Xenon Pharmaceuticals from $49.00 to $68.00 and gave the company an "overweight" rating in a report on Tuesday, March 10th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Xenon Pharmaceuticals has a consensus rating of "Buy" and a consensus price target of $73.13.

Insider Buying and Selling

In related news, insider Andrea Difabio sold 1,342 shares of the business's stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $55.23, for a total value of $74,118.66. Following the completion of the sale, the insider directly owned 7,301 shares in the company, valued at approximately $403,234.23. The trade was a 15.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Christopher John Kenney sold 1,410 shares of the business's stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $55.23, for a total value of $77,874.30. Following the completion of the sale, the insider owned 7,069 shares of the company's stock, valued at approximately $390,420.87. This trade represents a 16.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 296,707 shares of company stock worth $17,845,365. 4.07% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Walleye Capital LLC bought a new position in Xenon Pharmaceuticals in the 4th quarter worth approximately $878,000. Sei Investments Co. bought a new stake in shares of Xenon Pharmaceuticals during the second quarter valued at approximately $711,000. Oxford Asset Management LLP grew its position in Xenon Pharmaceuticals by 242.4% in the second quarter. Oxford Asset Management LLP now owns 21,138 shares of the biopharmaceutical company's stock valued at $662,000 after acquiring an additional 14,964 shares during the period. Creative Planning bought a new stake in Xenon Pharmaceuticals in the third quarter valued at $530,000. Finally, Himension Capital Singapore PTE. LTD. bought a new stake in Xenon Pharmaceuticals in the fourth quarter valued at $506,000. 95.45% of the stock is owned by institutional investors.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company's pipeline comprises multiple preclinical and clinical programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.